Inhibitor idelalisib active in non-Hodgkin lymphoma
The phosphatidylinositol-3-kinase delta inhibitor idelalisib shows antitumor activity in patients with indolent non-Hodgkin lymphoma and chronic lymphocytic leukemia.
The phosphatidylinositol-3-kinase delta inhibitor idelalisib shows antitumor activity in patients with indolent non-Hodgkin lymphoma and chronic lymphocytic leukemia.
The new drug idelalisib appears to offer hope for fighting slow-growing , or indolent, non-Hodgkin lymphomas (iNHLs). These lymphomas are difficult to treat, with most patients relapsing repeatedly and the disease becoming increasingly resistant to therapy over time. The phase 2 study involved 125 patients aged 33 to 87 years with indolent non-Hodgkin lymphoma (iNHL)…
This slideshow reviews vincristine, indicated for Hodgkin disease, Kaposi sarcoma, leukemia, neuroblastoma, non-Hodgkin lymphoma, rhabdomyosarcoma, and Wilms’ tumor.
In nearly one-third of patients with Waldenström macroglobulinemia, the disease is switched on by a specific genetic mutation. A new drug that blocks the defective gene can arrest the disease in animal models, according to research reported at the 2013 ASH Annual Meeting, in New Orleans.
A toxin linked to a targeted monoclonal antibody has shown compelling antitumor activity in patients with non-Hodgkin lymphomas (NHLs) who were no longer responding to treatment, according to a new report.
This slideshow examines bendamustine (Treanda), indicated for the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL).
Performing early stem cell transplants in patients with aggressive non-Hodgkin lymphoma does not improve overall survival in high-risk patients, according to a new study. However, early transplantation appears to be beneficial among the small group of patients who are at the very highest risk.
Assessing bone marrow involvement in persons with a new diagnosis of diffuse large B-cell lymphoma (DLBCL) is better accomplished with 18F-FDG positron emission tomography/computed tomography (PET/CT).
Survival rates were stable for patients with HIV-associated lymphoma during the antiretroviral therapy (ART) era in the United States, according to a new study.
Oral ibrutinib demonstrated durable single-agent efficacy in relapsed or refractory mantle-cell lymphoma in one study, and showed a high frequency of durable remissions in relapsed or refractory chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma in another study.